Andrew J. Muir, MD; Fred Poordad, MD; Jacob Lalezari, MD; et al.
This open-label uncontrolled study of patients with chronic HCV genotype 1 infection and cirrhosis reports high rates of SVR12 in those who received a 12-week oral fixed-dose regimen of daclatasvir, asunaprevir, and beclabuvir, with or without ribavirin.